Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
2.1% (consistent with weight loss rate) No Safety Signals: No increased risk of pancreatitis, thyroid tumors, or major CV events Historic Achievement: REDEFINE-1 demonstrated that CagriSema produces the highest mean weight loss (22.7%) ever reported for an obesity pharmacotherapy in a Phase 3 trial
Avoid injecting into broken skin, scar tissue, bruised or infected areas, moles, or sites showing signs of lipohypertrophy
We offer free consultations to discuss your weight loss goals and determine if Tirzepatide is the right option for you
CagriSema vs
If survodutide reaches market before retatrutide, it could provide early real-world evidence on glucagon receptor safety, which would benefit the retatrutide review process
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
